Molecular characterization of occult hepatitis B cases in Greek blood donors

Journal of Medical Virology

Volumn 81, Issue 5, 2009, Pages 815-825

  Katsoulidou, Antigoni ^a   Paraskevis, Dimitrios ^a   Magiorkinis, Emmanouil ^a   Moschidis, Zissis ^a   Haida, Catherine ^a   Hatzitheodorou, Eleni ^a   Varaklioti, Agoritsa ^b   Karafoulidou, Anastasia ^b   Hatzitaki, Maria ^c   Kavallierou, Lilian ^d   Mouzaki, Athanasia ^e   Andrioti, Evaggelia ^f   Veneti, Chrysanthi ^f   Kaperoni, Athanasia ^f   Zervou, Eleftheria ^g   Politis, Constantina ^h   Hatzakis, Angelos ^a,i  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c Blood Donation Center of Thessaly   (Greece)

^d A Fleming Blood Transfusion Center   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^h General Athens Hospital G Gennimatas   (Greece)

ⁱ National Retrovirus Reference Center   (Greece)

Author keywords

determinant; Blood donors; Nucleic acid testing; Phylogeny; Real time PCR; Sequence analysis

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; DIAGNOSTIC ERROR; DNA DETERMINATION; FEMALE; GENE SEQUENCE; GENOTYPE; GREECE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PHYLOGENY; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; STRUCTURAL GENE; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; AMINO ACID SUBSTITUTION; BLOOD DONORS; DNA, VIRAL; FEMALE; GENOTYPE; GREECE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 65649128909     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21499     Document Type: Article

References (75)

1. Allain JP. 2004. Occult hepatitis B virus infection: Implications in transfusion. Vox Sang 86:83-91.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677. (Pubitemid 28264693)
3. Ashton-Rickardt PG, Murray K. 1989. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol 29:196-203.
4. Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S, Chakrabarti S, Bhattacharya SK, Chakravarty R. 2007. Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. J Clin Virol 40:312-317.
5. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
6. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioglu A, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. 2003. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 38:506-510.
7. Bowden S, Bartholomeusz A, Locarnini S. 2003. Lamivudine resistant occult HBV: Implications for public health? J Hepatol 38:526-528.
8. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. 2001. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 34:194-203.
9. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M. 2006. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 44:1666-1674.
10. Brown SE, Howard CR, Zuckerman AJ, Steward MW. 1984. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet 2:184-187.
11. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, Schmidt M, Bird A, Crookes R, Brojer E, Miceli M, Amiri A, Li C, Allain JP. 2008. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 49:537-547.
12. Carman WF. 1997. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11-20.
13. Chen YC, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. 1996. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci USA 93:1997-2001.
14. Chen WN, Oon CJ, Toh I. 2000. Altered antigenicities of hepatitis B virus surface antigen carrying mutations outside the common "a" determinant. Am J Gastroenterol 95:1098-1099.
15. Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, Delage G. 2007. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 47:1794-1802.
16. Chong-Jin O, Wei Ning C, Shiuan K, Gek Keow L. 1999. Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. J Infect Dis 179:259-263.
17. Coleman PF, Chen YC, Mushahwar IK. 1999. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59:19-24.
18. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771-4779.
19. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
20. Gerlich WH, Wagner FF, Chudy M, Harrisjoh LH, Lattermaenn A, Sandra W. 2007. HBsAg non-reactive HBV infection in blood donors: Transmission and pathogenicity. J Med Virol 79:s32-s36.
21. Higgins DG, Sharp PM. 1988. CLUSTAL: A package for performing multiple sequence alignment on a microcomputer. Gene 73:237-244.
22. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. 2001. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 34:1027-1034.
23. Hu KQ. 2002. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9:243-257.
24. Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M. 2007. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 14:835-840.
25. Jeantet D, Chemin I, Mandrand B, Tran A, Zoulim F, Merle P, Trepo C, Kay A. 2004. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 73:508-515.
26. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, van Leeuwen EF. 1998. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 38:56-59.
27. Katsoulidou AS, Moschidis ZM, Gialeraki RE, Paraskevis DN, Sypsa VA, Lazanas MC, Tassopoulos NC, Psichogiou MA, Boletis JN, Karafoulidou AS, Hatzakis AE. 2004. Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion. Transfusion 44:59-66.
28. Katsoulidou A, Moschidis Z, Sypsa V, Chini M, Papatheodoridis GV, Tassopoulos NC, Mimidis K, Karafoulidou A, Hatzakis A. 2007. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang 92:8-14.
29. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA. 2005. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 45:1247-1257.
30. Kobayashi S, Ide T, Sata M. 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34:584-586.
31. Kreutz C. 2002. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 6:113-143.
32. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
33. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
34. Lelie N, Heaton A. 2006. Hepatitis B - A review of the role of NAT in enhancing blood safety. J Clin Virol 36:S1.
35. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. 2008. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 48:1022-1025.
36. Ling R, Harrison TJ. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 80:601-606.
37. Lok AS. 2002. Chronic hepatitis B. N Engl J Med 346:1682-1683.
38. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. 2004. Mutation of the "a" determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol 17:440-444.
39. Mahoney FJ. 1999. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12:351-366.
40. McAuley JD, Caglioti S, Williams RC, Robertson GF, Morgan L, Tobler LH, Busch MP. 2004. Clinical significance of nondiscriminated reactive results with the Chiron Procleix HIV-1 and HCV assay. Transfusion 44:91-96.
41. Mele A, Tancredi F, Romano L, Giuseppone A, Colucci M, Sangiuolo A, Lecce R, Adamo B, Tosti ME, Taliani G, Zanetti AR. 2001. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 184:905-908.
42. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
43. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A. 2005. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 42:480-485.
44. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M. 2004. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 50:159-162.
45. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
46. Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, Hopes E, Harrison TJ, Zuckerman AJ. 1995. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699-702.
47. Osiowy C. 2006. Detection of HBsAg mutants. J Med Virol 78:S48-S51.
48. Owusu-Ofori S, Temple J, Sarkodie F, Candotti D, Allain JP. 2005. Predonation testing of potential blood donors in resource-restricted settings. Transfusion 45:1542-1543.
49. Paraskevis D, Haida C, Tassopoulos N, Raptopoulou M, Tsantoulas D, Papachristou H, Sypsa V, Hatzakis A. 2002. Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J Virol Methods 103:201-212.
50. Paraskevis D, Haida C, Katsoulidou A, Moschidis Z, Hatzitheodorou E, Varaklioti A, Hatzakis A. 2007. Development of a flexible and sensitive in-house real-time PCR assay for the quantification of HBV DNA. Vox Sang 93:133.
51. Poch O, Sauvaget I, Delarue M, Tordo N. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8:3867-3874.
52. Politis CP, Karafoulidou A, Theodori H, Tsoukala A, Andrioti E, Tseliou P, Zervou E, Kavallierou L, Martinis G, Marantidou O, Kaperoni A, Hatzakis A. 2007. Occult hepatitis B surveillance in blood donations in Greece. Vox Sang 93:219.
53. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. 2006. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823-837.
54. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. 2007. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277-285.
55. Prange R, Mangold CM, Hilfrich R, Streeck RE. 1995. Mutational analysis of HBsAg assembly. Intervirology 38:16-23.
56. Sarafianos SG, Das K, Clark AD, Jr., Ding J, Boyer PL, Hughes SH, Arnold E. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 96:10027-10032.
57. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. 2007. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 47:1197-1205.
58. Seddigh-Tonekaboni S, Lim WL, Young B, Hou JL, Waters J, Luo KX, Thomas HC, Karayiannis P. 2001. Hepatitis B surface antigen variants in vaccinees, blood donors and an interferon-treated patient. J Viral Hepat 8:154-158.
59. Shaw T, Bartholomeusz A, Locarnini S. 2006. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 44:593-606.
60. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. 2006. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:427-434.
61. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
62. Swofford D. 2002. PAUP*: Phylogenetic analysis using parsimony (*and other methods), version 4. Sunderland, MA: Sinauer Associates.
63. Tabor E, Hoofnagle JH, Smallwood LA, Drucker JA, Pineda-Tamondong GC, Ni LY, Greenwalt TJ, Barker LF, Gerety RJ. 1979. Studies of donors who transmit posttransfusion hepatitis. Transfusion 19:725-731.
64. Thibault V, Aubron-Olivier C, Agut H, Katlama C. 2002. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16:131-133.
65. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680.
66. Torbenson M, Thomas DL. 2002. Occult hepatitis B. Lancet Infect Dis 2:479-486.
67. Torresi J. 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97-106.
68. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
69. Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, Alain S. 2004. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 18:569-571.
70. Wallace LA, Echevarria JE, Echevarria JM, Carman WF. 1994. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 170:1300-1303.
71. Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. 1992. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 22:1-12.
72. Weinberger KM, Zoulek G, Bauer T, Bohm S, Jilg W. 1999. A novel deletion mutant of hepatitis B virus surface antigen. J Med Virol 58:105-110.
73. Weinberger KM, Bauer T, Bohm S, Jilg W. 2000. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 81:1165-1174.
74. Westland C, Delaney WIV, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. 2003. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 125:107-116.
75. Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, Temple J, Allain JP. 2008. Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol 89:409-418.